Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients With Muscle-Invasive Bladder Cancer

Jonsson Comprehensive Cancer Center

Overview

This research trial studies quality of life after bladder-preservation chemotherapy and radiation therapy (chemo-radiotherapy) in patients with bladder cancer that has spread into or through the muscle layer of the bladder (muscle-invasive bladder cancer). Bladder-preservation chemo-radiotherapy is a standard treatment for patients with muscle-invasive bladder cancer, however, chemo-radiotherapy may cause urinary tract, bowel, and sexual late side effects that negatively affect patients' quality of life. Studying quality-of-life in patients with muscle-invasive bladder cancer after chemo-radiotherapy may help identify the long-term side effects of treatment and may help plan the best treatment in the future and improve patients' quality of life.

PRIMARY OBJECTIVES: I. To study health-related quality of life (HRQoL, or QOL) for patients undergoing protocol-based bladder-preservation chemo-radiation. OUTLINE: Patients complete the European Organization for Research and Treatment for Cancer (EORTC) QLQ-Bladder Cancer Muscle Invasive (BLM-C30) at baseline, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter after completion of chemo-radiotherapy.

Study Type

INTERVENTIONAL

Allocation

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Conditions

Infiltrating Bladder Urothelial Carcinoma

Interventions

Quality-of-Life AssessmentOTHER

Ancillary studies

Questionnaire AdministrationOTHER

Ancillary studies

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically confirmed muscle-invasive urothelial cancer (no histology will be excluded) * No pelvic nodal metastases or distant metastases (based on computed tomography \[CT\], positron emission tomography \[PET\] or magnetic resonance imaging \[MRI\]) * Karnofsky performance status (KPS) \>= 70 * Ability to understand, and willingness to sign, the written informed consent * Patient will have either opted for bladder-sparing treatment as compared to radical cystectomy, or deemed medically inoperable * Following the recent recommendations from the International Consultation on Urological Diseases-European Association of Urology International Consultation on Bladder Cancer, eligible patients will be those with no hydronephrosis, no extensive carcinoma in situ (CIS), and no tumor invasion into the stroma of the prostate Exclusion Criteria: * Patients with any evidence of distant metastases * Prior pelvic radiotherapy * History of Crohn's disease or ulcerative colitis * Unable to receive chemotherapy * Histologies other than urothelial (eg. squamous cell carcinoma, adenocarcinoma, small cell)

Locations (1)

UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, United States

Outcomes

Primary Outcomes

Establish QOL with validated tools for patients undergoing bladder-preservation chemo-radiation

Validated Quality-of-Life questionnaires developed by the European Organization for Research and Treatment for Cancer (EORTC) will be used. The EORTC QLQ-BLM30 with 30 questions specific to muscle-invasive bladder cancer will be combined and used in conjunction with the general cancer questionnaire EORTC QLQ-C30 (Aaronson).

Time frame: From the date of study entry up to 5 years

Secondary Outcomes

Quantify the rate of early and late grade 3 or higher GU or GI toxicity based on the CTCAE criteria

Time frame: Up to 5 years

Overall survival

Time frame: From the date of study entry to the date of death, assessed up to 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.